GlaxoSmithKline Pharmaceuticals Ltd represents values and a corporate philosophy centered on innovation, integrity, and patient-focused healthcare. As a leading pharmaceutical company, GlaxoSmithKline is committed to discovering, developing, and delivering high-quality medicines that improve people's lives. Their philosophy revolves around ethical business practices, stringent quality standards, and adherence to regulatory norms. By leveraging cutting-edge research and technology, GlaxoSmithKline aims to address critical healthcare challenges and contribute to societal well-being. With a strong emphasis on sustainability, they are dedicated to reducing environmental impact and promoting responsible business practices. GlaxoSmithKline Pharmaceuticals Ltd's relentless pursuit of scientific excellence and commitment to serving patients underscores their reputation as a trusted and renowned pharmaceutical entity.

GlaxoSmithKline Pharmaceuticals Ltd is primarily present in various countries and regions. The company has a strong global presence and operates in multiple markets. Some of the key countries where GlaxoSmithKline Pharmaceuticals Ltd has a significant presence include the United Kingdom, United States, India, China, Japan, Australia, the European Union, and many more. With its extensive reach, GlaxoSmithKline Pharmaceuticals Ltd continues to expand its operations and serve customers in diverse geographical locations.

GlaxoSmithKline Pharmaceuticals Ltd has achieved several significant milestones. Notably, the company has consistently demonstrated its commitment to innovation and has been at the forefront of discovering and developing life-saving medications. With a strong focus on research and development, GlaxoSmithKline Pharmaceuticals Ltd has successfully launched numerous breakthrough drugs that have revolutionized healthcare. Additionally, the company has maintained a stellar track record in ensuring high-quality and affordable pharmaceutical products for patients across the globe. With its unwavering dedication to advancing healthcare, GlaxoSmithKline Pharmaceuticals Ltd continues to achieve remarkable milestones in improving the overall well-being of people worldwide.

GlaxoSmithKline Pharmaceuticals Ltd, a leading pharmaceutical company, has a rich history and background. Established in 1924, it has evolved into a trusted healthcare provider. GlaxoSmithKline Pharmaceuticals specializes in the research, development, and manufacturing of innovative medicines and vaccines. With a strong presence in India, it has played a pivotal role in the country's healthcare sector. As a subsidiary of GlaxoSmithKline plc, a global pharmaceutical company, it benefits from the extensive expertise and resources of its parent company. GlaxoSmithKline Pharmaceuticals is dedicated to enhancing the quality of life and contributing to the well-being of individuals through its cutting-edge healthcare solutions.

The main competitors of GlaxoSmithKline Pharmaceuticals Ltd in the market are Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, and Cipla Ltd.

GlaxoSmithKline Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.

The business model of GlaxoSmithKline Pharmaceuticals Ltd is focused on the research, development, manufacturing, and marketing of pharmaceutical products. As a leading pharmaceutical company, GlaxoSmithKline Pharmaceuticals Ltd produces a wide range of medicines across various therapeutic areas, including respiratory, anti-infective, dermatology, and more. The company aims to improve the quality of human life by delivering innovative and high-quality healthcare solutions. With a strong commitment to research and development, GlaxoSmithKline Pharmaceuticals Ltd strives to address unmet medical needs and provide accessible and affordable healthcare options to patients worldwide.

GlaxoSmithKline Pharmaceuticals KGV ir 79,41.

GlaxoSmithKline Pharmaceuticals KUV ir 13,56.

AlleAktien kvalitātes vērtējums GlaxoSmithKline Pharmaceuticals ir 9/10.

GlaxoSmithKline Pharmaceuticals apgrozījums ir 34,54 miljardi INR.

GlaxoSmithKline Pharmaceuticals peļņa ir 5,90 miljardi INR.

The company GlaxoSmithKline Pharmaceuticals Ltd is a global company that manufactures and distributes various health products and pharmaceuticals. It was founded in 2000 through the merger of the British pharmaceutical company GlaxoWellcome and the American corporation SmithKline Beecham. The business model of GlaxoSmithKline Pharmaceuticals is based on the production of prescription and over-the-counter medications for various therapeutic areas. The company is divided into three divisions: Pharma, Vaccines, and Consumer Healthcare. In the Pharma division, GlaxoSmithKline manufactures innovative medications for areas such as oncology, diabetes, and respiratory diseases. These are primarily prescription drugs prescribed by doctors. The Vaccine division develops and produces vaccines for different infectious diseases such as meningitis or HPV. Consumer Healthcare, on the other hand, offers over-the-counter medications for colds, pain, and gastrointestinal issues. Some of the well-known medications produced by GlaxoSmithKline Pharmaceuticals include Zovirax (for herpes), Advair (for asthma), Voltaren (for pain), and Panadol (for pain and fever). The company also has products for HIV/AIDS therapy, such as Tivicay. In the Vaccine division, the company offers products such as Hepatitis A and B vaccines, the HPV vaccine Cervarix, and the pneumococcal vaccine Synflorix. Consumer Healthcare distributes over-the-counter products such as Otrivin (for nasal congestion), Nicorette (for smoking cessation), and Sensodyne (for sensitive teeth). The company continuously invests in research and development to develop new medications and improve existing products. In 2019, GlaxoSmithKline Pharmaceuticals' research and development budget was almost 4 billion euros. Additionally, the company works closely with government agencies and other partners to combat global health issues. For example, GlaxoSmithKline Pharmaceuticals is involved in an immunization program for children in developing countries. The company distributes its products worldwide, operating in more than 150 countries. The company's headquarters are located in Brentford, United Kingdom. It also has a presence in Germany, with a location in Munich. In summary, GlaxoSmithKline Pharmaceuticals Ltd is a leading company in the pharmaceutical and healthcare products industry. Its business model is based on the production of prescription and over-the-counter medications as well as vaccines. The company's close collaboration with government agencies and partners makes it an important player in the fight against global health issues.

GlaxoSmithKline Pharmaceuticals izmaksā dividendes 30,00 INR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt GlaxoSmithKline Pharmaceuticals vai uzņēmums nedod dividendes.

GlaxoSmithKline Pharmaceuticals ISIN ir INE159A01016.

GlaxoSmithKline Pharmaceuticals simbols ir GLAXO.NS.

Pēdējo 12 mēnešu laikā GlaxoSmithKline Pharmaceuticals maksāja dividendes 32,00 INR apmērā. Tas atbilst aptuveni 1,16 % dividendes ražībai. Nākamajos 12 mēnešos GlaxoSmithKline Pharmaceuticals plāno maksāt dividendes 30,32 INR apmērā.

GlaxoSmithKline Pharmaceuticals pašreizējā dividendu rentabilitāte ir 1,16 %.

GlaxoSmithKline Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos augusts, augusts, jūlijs, jūlijs.

GlaxoSmithKline Pharmaceuticals pēdējo 23 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 30,32 INR. Tas atbilst dividendes ražībai 1,10 %.

GlaxoSmithKline Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu GlaxoSmithKline Pharmaceuticals apmērā 32 INR, kas tika izmaksāta 1.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 31.05.2024..

Pēdējās dividendes izmaksa notika 1.07.2024..

Gadā 2023, GlaxoSmithKline Pharmaceuticals izmaksāja 32 INR dividendes.

GlaxoSmithKline Pharmaceuticals dividendes tiek izmaksātas INR.